Fagron NV

Brussels Stock Exchange FAGR.BR

Fagron NV Return on Assets (ROA) for the year ending December 31, 2023: 7.01%

Fagron NV Return on Assets (ROA) is 7.01% for the year ending December 31, 2023, a -2.27% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Fagron NV Return on Assets (ROA) for the year ending December 31, 2022 was 7.17%, a -5.94% change year over year.
Fagron NV Return on Assets (ROA) for the year ending December 31, 2021 was 7.62%, a -3.73% change year over year.
Fagron NV Return on Assets (ROA) for the year ending December 31, 2020 was 7.92%, a 13.91% change year over year.
Fagron NV Return on Assets (ROA) for the year ending December 31, 2019 was 6.95%, a 11.69% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Brussels Stock Exchange: FAGR.BR

Fagron NV

CEO	Mr. Rafael Padilla
IPO Date	Oct. 5, 2007
Location	Belgium
Headquarters	Venecoweg 20A
Employees	3,647
Sector	Health Care
Industries Pharmaceuticals

Description

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Key trends

Past 5 years